Puma Biotechnology (PBYI) Competitors $4.99 -0.26 (-4.95%) Closing price 08/25/2025 04:00 PM EasternExtended Trading$5.07 +0.08 (+1.60%) As of 05:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PBYI vs. ADMA, CTMX, TRDA, TLRY, RCUS, LENZ, ZYME, SYRE, UPB, and STOKShould you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include ADMA Biologics (ADMA), CytomX Therapeutics (CTMX), Entrada Therapeutics (TRDA), Tilray Brands (TLRY), Arcus Biosciences (RCUS), LENZ Therapeutics (LENZ), Zymeworks (ZYME), Spyre Therapeutics (SYRE), Upstream Bio (UPB), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry. Puma Biotechnology vs. Its Competitors ADMA Biologics CytomX Therapeutics Entrada Therapeutics Tilray Brands Arcus Biosciences LENZ Therapeutics Zymeworks Spyre Therapeutics Upstream Bio Stoke Therapeutics ADMA Biologics (NASDAQ:ADMA) and Puma Biotechnology (NASDAQ:PBYI) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends. Is ADMA or PBYI more profitable? ADMA Biologics has a net margin of 44.06% compared to Puma Biotechnology's net margin of 20.38%. Puma Biotechnology's return on equity of 53.15% beat ADMA Biologics' return on equity.Company Net Margins Return on Equity Return on Assets ADMA Biologics44.06% 41.01% 28.47% Puma Biotechnology 20.38%53.15%23.51% Which has more risk and volatility, ADMA or PBYI? ADMA Biologics has a beta of 0.38, indicating that its share price is 62% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.3, indicating that its share price is 30% more volatile than the S&P 500. Do insiders & institutionals have more ownership in ADMA or PBYI? 75.7% of ADMA Biologics shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 3.7% of ADMA Biologics shares are held by insiders. Comparatively, 23.3% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend ADMA or PBYI? ADMA Biologics currently has a consensus target price of $27.67, indicating a potential upside of 62.65%. Puma Biotechnology has a consensus target price of $7.00, indicating a potential upside of 40.28%. Given ADMA Biologics' stronger consensus rating and higher probable upside, analysts plainly believe ADMA Biologics is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, ADMA or PBYI? ADMA Biologics has higher revenue and earnings than Puma Biotechnology. Puma Biotechnology is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADMA Biologics$426.45M9.52$197.67M$0.8619.78Puma Biotechnology$230.50M1.09$30.28M$0.985.09 Does the media favor ADMA or PBYI? In the previous week, ADMA Biologics had 5 more articles in the media than Puma Biotechnology. MarketBeat recorded 5 mentions for ADMA Biologics and 0 mentions for Puma Biotechnology. ADMA Biologics' average media sentiment score of 1.68 beat Puma Biotechnology's score of 0.75 indicating that ADMA Biologics is being referred to more favorably in the media. Company Overall Sentiment ADMA Biologics Very Positive Puma Biotechnology Positive SummaryADMA Biologics beats Puma Biotechnology on 13 of the 17 factors compared between the two stocks. Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBYI vs. The Competition Export to ExcelMetricPuma BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$264.45M$3.12B$5.82B$9.74BDividend YieldN/A2.24%4.40%4.08%P/E Ratio5.0920.7730.1625.84Price / Sales1.09345.85432.33103.25Price / Cash6.1643.2325.7828.79Price / Book2.659.649.525.99Net Income$30.28M-$54.08M$3.27B$265.29M7 Day Performance-1.96%3.85%3.17%3.87%1 Month Performance52.13%2.54%3.11%0.75%1 Year Performance88.30%6.59%31.47%18.20% Puma Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBYIPuma Biotechnology3.9267 of 5 stars$4.99-5.0%$7.00+40.3%+96.5%$264.45M$230.50M5.09200ADMAADMA Biologics4.2774 of 5 stars$17.63+3.8%$27.67+56.9%-7.6%$4.05B$474.17M20.50530Positive NewsCTMXCytomX Therapeutics3.8492 of 5 stars$2.12+11.0%$5.75+171.2%+65.3%$314.98M$138.10M3.79170High Trading VolumeTRDAEntrada Therapeutics2.9139 of 5 stars$5.52+4.7%$25.67+365.0%-65.9%$200.46M$210.78M-3.10110TLRYTilray Brands2.2727 of 5 stars$1.14+10.7%$1.92+68.1%-28.0%$1.13B$821.31M-0.492,842Analyst ForecastOptions VolumeGap UpRCUSArcus Biosciences2.3905 of 5 stars$10.45+0.6%$21.14+102.3%-43.5%$1.11B$258M-3.30500LENZLENZ Therapeutics1.809 of 5 stars$38.77+2.4%$49.60+27.9%+76.4%$1.08BN/A-20.41110ZYMEZymeworks0.2096 of 5 stars$14.05-2.2%N/AN/A$1.08B$76.30M-14.48460SYRESpyre Therapeutics2.4113 of 5 stars$16.94-0.1%$53.40+215.2%-35.1%$1.02B$890K-4.9873News CoverageAnalyst UpgradeUPBUpstream Bio2.1171 of 5 stars$18.02-4.8%$56.50+213.5%N/A$1.02B$2.37M0.0038STOKStoke Therapeutics4.444 of 5 stars$18.51+1.6%$25.57+38.1%+34.9%$997.86M$36.56M21.78100 Related Companies and Tools Related Companies ADMA Biologics Competitors CytomX Therapeutics Competitors Entrada Therapeutics Competitors Tilray Brands Competitors Arcus Biosciences Competitors LENZ Therapeutics Competitors Zymeworks Competitors Spyre Therapeutics Competitors Upstream Bio Competitors Stoke Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBYI) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access